Market StrategyManagement's expansion efforts, including increasing the sales force, have led to rising patient demand and market share for Lumryz.
Regulatory ApprovalLUMRYZ received Orphan Drug Designation from the FDA for idiopathic hypersomnia, highlighting its clinical superiority.
Sales GrowthAvadel Pharmaceuticals announced an increase in expected patient numbers and revenue for Lumryz, indicating strong future growth.